Study summary

A weekly at-home injection of lecanemab was approved

Leqembi injection · Clarity AD extension · FDA approval reported July 13, 2026

What was tested

A under-the-skin autoinjector version of lecanemab, tested in the extension of the Clarity AD trial against the infusion.

What they found

• Approved for starting treatment as well as continuing it, so infusions are no longer required.
• Drug levels in the blood were comparable to the infusion.
• Each injection takes about 15 seconds.

What it means

Removes the infusion-center bottleneck that limited who could get treatment. Scan monitoring is still needed.